TTRX
$3.62
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
Intraday
Recent News
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics (NASDAQ:TTRX) executives outlined the company’s focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an Oppenheimer-hosted event. CEO and founder Bradley Burnam, joined by CFO Zuraiz Chaudhary, emphasized the company
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying
Key Insights Significant insider control over Turn Therapeutics implies vested interests in company growth Bradley...
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average ... Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More